Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the ...

The final, formatted version of the article will be published soon. Abstract: Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized cancer treatment, yet its application remains limited ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Allogeneic CD19 chimeric antigen receptor-natural killer (CAR-NK) cell therapy showed promise in patients with relapsed or refractory systemic lupus erythematosus (SLE), with sustained efficacy. The ...

New from @hopkinskimmel: Researchers developed a TRBC2-targeting antibody–drug conjugate that selectively kills T-cell cancers while sparing healthy T cells in mice and lab models. The work expands a ...

It’s not unusual for cats to have the occasional upset stomach, but when issues persist, something more serious could be going on. One possible hidden cause is small cell gastrointestinal (GI) ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Ann S. LaCasce, MD, MMSc, discusses highlights in mantle cell lymphoma presented at ASH ...